SRR1458595
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- CHOLESTEROL_HOMEOSTASIS+0.405
- IL6_JAK_STAT3_SIGNALING+0.395
- TNFA_SIGNALING_VIA_NFKB+0.376
- INFLAMMATORY_RESPONSE+0.366
- PROTEIN_SECRETION+0.359
- INTERFERON_GAMMA_RESPONSE+0.354
- IL2_STAT5_SIGNALING+0.350
- TGF_BETA_SIGNALING+0.338
- ANGIOGENESIS+0.331
- ALLOGRAFT_REJECTION+0.316
Top 10 suppressed
- PANCREAS_BETA_CELLS-0.491
- HEDGEHOG_SIGNALING-0.441
- SPERMATOGENESIS-0.202
- KRAS_SIGNALING_DN-0.195
- MYC_TARGETS_V2-0.188
- OXIDATIVE_PHOSPHORYLATION-0.146
- E2F_TARGETS-0.090
- APICAL_SURFACE-0.077
- WNT_BETA_CATENIN_SIGNALING-0.073
- DNA_REPAIR-0.070
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1085782 | GTEX | — | 0.927 |
| 2 | SRR660895 | GTEX | — | 0.926 |
| 3 | SRR1388007 | GTEX | — | 0.910 |
| 4 | SRR1446828 | GTEX | — | 0.905 |
| 5 | SRR934729 | — | — | 0.898 |
| 6 | B5DE434D-6630-4E7E-BA91-6DAC5E2608D3 | — | — | 0.880 |
| 7 | SRR934811 | — | — | 0.878 |
| 8 | SRR934945 | — | — | 0.876 |
| 9 | 7E4D42B3-FD9B-4184-A4A0-E52E45259428 | — | — | 0.874 |
| 10 | BS_J4GQPZS0 | Schwannoma | — | 0.874 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 38 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| CHOLESTEROL_HOMEOSTASIS | 0.405 | Remibrutinib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.395 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.376 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.366 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.359 | Remibrutinib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.354 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.350 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.338 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.331 | Remibrutinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.316 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.314 | Inavolisib | — uncovered |
| APOPTOSIS | 0.301 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.298 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.297 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.294 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.290 | Inavolisib | — uncovered |
| COMPLEMENT | 0.266 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.266 | Inavolisib | — uncovered |
| HYPOXIA | 0.262 | Idelalisib | — uncovered |
| PEROXISOME | 0.254 | Idelalisib | — uncovered |